INNOVATIVE SOLUTIONS
AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.
AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.
ALTB-168
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Phase II
Phase 2a Psoriasis trials completed with signs of clinical efficacy achieved.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Phase II
Phase 2a Psoriatic Arthritis trial completed with signs of clinical efficacy demonstrated.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Phase II
Phase 2a anti-TNFα and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with signs of clinical efficacy demonstrated; continued UC development planned with ALTB-268.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Phase I
Phase 1b multi-dose steroid/treatment refractory acute graft versus host disease trial completed with signs of clinical efficacy.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Phase I
Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
ALTB-268
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Phase II
Potency improved version of ALTB-168, Phase 1 trial in healthy volunteers completed. Ph2a trial in UC patients initiated in late 2023.
Apr, 2024
AltruBio
top